LTL-365 datasheet

Origin	Primary human ovarian cancer	**Histopathology**	Clear cell carcinoma
Year of establishment	2010	**Doubling time**	Not determined (in early generations)
Local invasion	No	**Metastasis**	No

The LTL-365 (Figure 1) was developed from a patient's primary ovarian cancer (high-grade (grade 3/3) celar cell carcinoma). When grafted under the renal capsules of SCID mice, the LTL-365 shows no local invasion into adjacent host kidney parenchyma and no metastasis to distant organs.



Fig 1. H&E stained LTL-365 tissue sections.

The LTL-365 are composed of flat to cuboidal hobnail or clear cells grown in a papillary pattern. Sevel papillae contain hyalinized esoinophilic cores. (x200)

Genetic and epigenetic characteristics

Tissue microarrays containing LTL-365 tissue are available for screening potential molecular targets.

Applications

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), and angiogenesis.

2. Discovery of potential therapeutic and/or biomarkers for drug sensitivity targets.

3. Study of mechanisms underlying tumor growth and progression.

References

1. Lee et al., Gynecologic Oncology 2005; 96: 48-55

2. Press et al., Gynecologic Oncology 2008; 110: 256-264

For more information, please contact us by email: LTL@bccrc.ca or phone: (604) 675 8013